Rhumbline Advisers Pardes Biosciences, Inc. Transaction History

Rhumbline Advisers

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 08, 2023	SELL	$1.4 - $1.95 $60,512 - $84,284	-43,223 Reduced 88.11%	5,832 $10,000
Q1 2023 May 11, 2023	BUY	$1.21 - $2.22 $3,057 - $5,609	2,527 Added 5.43%	49,055 $65,000
Q4 2022 Feb 14, 2023	BUY	$0.85 - $1.69 $757 - $1,505	891 Added 1.95%	46,528 $79,000
Q3 2022 Nov 10, 2022	BUY	$2.14 - $3.7 $9,766 - $16,886	4,564 Added 11.11%	45,637 $84,000
Q2 2022 Aug 11, 2022	BUY	$2.84 - $8.57 $116,647 - $351,995	41,073 New	41,073 $126,000

5.23M

Ticker PRDS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 62,320,900
Description
Pardes Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics to improve the lives of patients suffering from life-threatening disease. Its lead candidate is the PBI-0451 that is in clinical development stage to treat and prevent severe acute respiratory syndrome ...

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

Stay updated on Rhumbline Advisers with notifications on news.